NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors

  • Industry Veteran and Immune Oncologist with over 35 years’ Experience in the Life Sciences Industry and Drug Development

Basel, Switzerland, August 10, 2020: NBE-Therapeutics, the Swiss-based company developing best-inclass cancer therapies based on its proprietary, highly differentiated Antibody Drug Conjugate (ADC) platform, announces the appointment of Prof. Dr. Erich Schlick as Independent Chairman of its Board of Directors.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...